Feed RPRX
RP

Royalty Pharma RPRX NASDAQ · Healthcare · United States

$67.72 -1.38% -$0.95

Summary

53 / 100 · Bulios Score

What speaks for it

  • Earnings per share grew by 162% a year over the last 3 years.
  • Out of every 100 USD of revenue, 26 USD is left as net profit.
  • It has raised its dividend 5 years in a row.
  • It bought back its own shares for $1.23B in the last fiscal year, 4.0% of its market value.

What to watch

  • Repaying its net debt would take 5.2 years of operating profit.
  • You pay 45.5 USD for 1 USD of yearly profit, a lot for its sector.
  • Revenue grew by only 2.1% a year over the last 3 years.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced
Bulios Fair Price
Fair Value Price today $67.72

By our assumptions the price matches the value of the business: the two differ by less than 10 %.

P/E today 45.5 54% lower
5-year average P/E 98.3
P/E today 45.5
Medical - Pharmaceuticals industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 45.5 USD for 1 USD of yearly profit. Over the last five years it was 98.3 USD on average.

Valuation in detail

Is it growing?

Slowly

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 2.3% a year over 5 years. Over the last 3 years it grew by 2.1% a year. Earnings per share grew by 162% a year over the last 3 years.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Medical - Pharmaceuticals) 6.3 USD

Out of every 100 USD of revenue, 26 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

Repaying all its debt would take 2.9 years of free cash flow. Its debt is larger than its cash. The debt score is low because of the debt-to-equity ratio (1.3x).

Financial health in detail

Does it pay a dividend?

Small, stretched
Yield
1.37%
Paid out of profit
62%
Raised in a row
5 years

You receive $0.94 per share a year. The payout takes a large part of its profit or free cash flow.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $66.5 is 1.8% below today's price. 100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

The company reports no revenue by region.

Financial Royalty Assets brings in 95% of revenue. Royalty Income, Other grew fastest, by 22% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy